Robust pipeline provides potential for long-term value creation, establishing Sage as a leader in brain health
Rolling New Drug Application (NDA) submission for zuranolone in MDD and PPD complete, with potential for PDUFA date as early as the third quarter of 2023 if priority review is received and other timelines meet expectations
Progressing nine ongoing studies across zuranolone, SAGE-718, SAGE-324 and early pipeline programs
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.